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ABSTRACT
Very little is known regarding the affects of the microgravity environment of
space flight upon the action of antimicrobial agents on bacterial pathogens. This study
was undertaken to develop a simple method for conducting antibacterial susceptibility
tests during a Space Shuttle mission. Specially prepared susceptibility test research
cards (bioMerieux Vitek, Hazelwood, MO) were designed to include 6-11 serial two-
fold dilutions of 14 antimicrobial agents, including penicillins, cephalosporins, a t_-
lactamase inhibitor, vancomycin, erythromycin, tetracycline, gentamicin, ciprofloxacin,
and trimethoprim/sulfamethoxazole. Minimal inhibitory concentrations (MICs) of the
drugs were determined by visual reading of color endpoints in the Vitek research cards
made possible by incorporation of a colorimetric growth indicator (alamarBlue TM,
Accumed International, Westlake, OH). This study has demonstrated reproducible
susceptibility results when testing isolates of Staphylococcus aureus, Group A
Streptococcus, Enterococcus faecalis, Escherichia coli (beta-lactamase positive and negative
strains), Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. In some
instances, the MICs were comparable to those determined using a standard broth
microdilution method, while in some cases the unique test media and format yielded
slightly different values, that were themselves reproducible. The proposed in-flight
experiment will include inoculation of the Vitek cards on the ground prior to launch of
the Space Shuttle, storage of inoculated cards at refrigeration temperature aboard the
Space Shuttle until experiment initiation, then incubation of the cards for 18-48 h prior
to visual interpretation of MICs by the mission's astronauts. Ground-based studies
have shown reproducible MICs following storage of inoculated cards for 7 days at 4-
8oc to accommodate the mission's time schedule and the astronauts' activities. For
comparison, ground-based control (normal gravity) MIC values will be generated by
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simultaneous inoculation and incubation of a second set of test cards in a laboratory at
the launch site. This procedure can provide a safe and compact experiment that should
yield new information on the affects of microgravity on the biological activities of
various classes of antibiotics.
INTRODUCTION
Extended space flight missions of greater than 90 days aboard the Russian Space
Station Mir are currently underway and even longer duration missions on the
International Space Station are planned during this decade. Early studies in the space
craft environment showed distinct effects on microorganisms, including apparent
increased growth rates and increased cell density (4). Relatively little is known about
the effect of microgravity during space flight on the susceptibility of bacteria to
antimicrobial agents. Bacteria recovered from astronauts during the Apollo-Soyuz Test
Project in 1975 demonstrated somewhat increased antimicrobial resistance in post flight
isolates as compared to pre-flight baseline isolates (1,10,13). Limited antimicrobial
susceptibility studies were performed by a French-Soviet team involved with the Salyut
7 spacecraft mission in 1982 (3,14). Isolates of Staphylococcus aureus and Escherichia coli
recovered from one of the cosmonauts were tested in vitro against five antibiotics
during the flight. Resistance was said to increase in both organisms, as indicated by
MICs of oxacillin, chloramphenicol, and erythromycin against S. aureus that were
found to be approximately twice the ground-based control values, and the MICs for
colistin and kanamycin against E. coli were more than four-fold higher than in ground-
based controls (4,6,14). In a 1985 experiment during the Spacelab D1 mission
(European Space Agency giorack program), increased resistance to a single antibiotic,
colistin, was demonstrated a second time (6,14). In this experiment, in-flight cultures of
E. coli were tested against colistin in a static incubator (microgravity conditions) and in
a centrifuge that simulated 1 g. Increased resistance was evident in the in-flight tests as
compared to the ground- and flight- controls.
Postflight analyses of microorganisms collected from in-flight experiments have
indicated that the space-grown microbes, after subculture several times on the ground,
return to normal levels of antibiotic susceptibility (3,13,14). From the results of these
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initial experiments, the apparent increasein resistancedid not appear to be an acquired
characteristic of the organisms,but rather a temporary adaptation to conditions of
microgravity. Electron-microscopy of space-grown cultures have shown an increasein
cell-wall thickness (3). This may have altered cellular permeability, thus affecting the
penetration of antibiotics into the cells. However, increasedresistance to antibiotics due
to temporary modification of molecular targets or alterations in cell physiology cannot
be excluded. Thus, there is some evidence that a microgravity environment adversely
affects some drugs or classes of drugs, which could have clinical significance in the
eventuality of astronaut illness during prolonged missions.
The constraints associated with space flight do not allow the use of traditional
antibiotic susceptibility testing methods. Safety issues preclude transferring liquids
containing viable microorganisms to prepare and standardize inocula for susceptibility
tests, and open tubes or plates of broth or agar cannot be handled safely without a
burdensome biological safety cabinet. The purpose of this study was to design a
simple, safe susceptibility testing procedure suitable to be conducted on an upcoming
Space Shuttle mission that would evaluate several antimicrobial agents of current
therapeutic relevance against common bacterial pathogens. A susceptibility test
method has been developed that uses specially prepared antibiotic research test cards
(bioMerieux Vitek, Hazelwood, MO) incorporating a growth indicator (alamarBlue_M;
Accumed, Westlake, OH) for manual susceptibility determinations by astronauts
during a Space Shuttle mission.
MATERIALS AND METHODS
Bacterial test strains. A group of commonly occurring bacterial pathogens consisting of
both ATCC stock cultures and selected clinical isolates were utilized in these studies.
These included Staphylococcus aureus ATCC 29213, Group A Streptococcus, Enterococcus
faecalis ATCC 29212, Escherichia coli ATCC 25922 and 35218, Pseudomonas aeruginosa
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ATCC 27853,Klebsiella pneumoniae, and Enterobacter cloacae. Several of the strains were
selected because of known susceptibility or resistance to the study antimicrobial agents.
Antimicrobial agents selected for study. Antimicrobial agents were chosen for
inclusion in the study based on their potential clinical utility and because they
represented examples of different chemical classes and modes of antimicrobial action.
These included the cell wall active agents penicillins, cephalosporins, and vancomycin;
the beta-lactamase inhibitor clavulanate (combined with amoxicillin); protein synthesis
inhibitors, tetracycline, erythromycin, and gentamicin; a DNA gyrase inhibitor,
ciprofloxacin; and the folate metabolism inhibitors trimethoprim/sulfamethoxazole.
Specially prepared Vitek cards. Specially configured Vitek research susceptibility
testing cards were kindly provided for this study by bioMerieux Vitek. The cards
incorporated log2 dilutions of the study antibiotics without growth medium in standard
30 well clear plastic Vitek cards. The test concentrations of each antibiotic were selected
in order to encompass a range of approximately two dilutions on either side of the
expected MICs for each test strain. Cards 1 and 2 used for gram-positive bacteria
included penicillin, 0.008-8 _tg/ml; oxacillin, 0.03-2 lag/ml; cephalothin 0.008-0.5
_g/ml; vancomycin 0.12-16 _tg/ml; ciprofloxacin, 0.06-16 _g/ml; erythromycin, 0.06-16
_tg/ml; and trimethoprim/sulfamethoxazole, 0.25-16 _tg/ml (based on the trimethoprim
component tested in a fixed 1:19 ratio). For gram negative test species, cards 3 and 4
contained ampicillin, 1-32 _tg/ml; amoxicillin/clavulanate, 2-64 _tg/ml (based on the
amoxicillin component tested in a fixed 2:1 ratio); cephalothin, 4-128 _tg/ml;
cefuroxime, 0.5-8 _tg/ml; ceftazidime, 0.06-8 _tg/ml; gentamicin, 0.12-32 _g/ml;
tetracycline, 1-32 _tg/ml; ciprofloxacin, 0.004-0.12 _tg/ml, and trimethoprim/
sulfamethoxazole, 0.06-2 _tg/ml (based on the trimethoprim component).
Specially formulated test media. Growth media were selected and optimized based on
preliminary experiments for each organism or group as indicated below. In order to
make manual readings of the Vitek cards possible, a redox growth indicator
(alamarBlueTM U.S. patent no. 5,501,959; kindly provided by Alamar Biosciences [now
Accumed, International, Westlake, Ohio]) was incorporated into each test medium. The
indicator system allowed growth of a test organism to be visually detected when the
indicator turned from blue to bright pink. Preliminary experiments were conducted to
define a suitable test medium and optimal indicator concentration for each test
organism. For the staphylococci, Enterobacteriaceae and P. aeruginosa, the test medium
consisted of cation adjusted Mueller-Hinton broth (Difco Laboratories, Detroit, MI), 1%
yeast extract (Difco) and triple strength alamarBlue TM (equivalent to 0.0045% resazurin).
For Group A Streptococcus and E. faecalis, BBL Sceptor Gram-Positive Broth (Becton-
Dickinson Microbiology Systems, Sparks, MD) was chosen for these experiments and
double strength alamarBlue TM (equivalent to 0.003% resazurin) was used.
Inoculation of the Vitek cards. The Vitek cards were simultaneously filled with test
medium and inoculated by using the test medium as the final diluent for the bacterial
inoculum. This was accomplished by first preparing a fresh bacterial suspension in
0.45% saline equivalent in turbidity to a 0.5 McFarland standard. For gram-positive
organisms, 100 _tl of a 1:10 dilution (in saline) of the 0.5 McFarland suspension was
added to 1.8 ml of the special test medium described above. For gram-negatives, 50 _1
of a 1:10 dilution of the McFarland suspension was placed in 1.8 ml of test medium.
The inoculated test media were then used to fill the Vitek cards using a Vitek vacuum-
filling module in the usual manner. The final inoculum density in each well of the filled
Vitek cards was approximately 1-3 x 105 CFU/ml.
Storage and incubation of the Vitek cards. The inoculated cards were placed in a
standard Vitek card holder and then either placed in a standard 35°C bacteriologic
incubator or stored at 4-8°C for a defined period prior to incubation. In most
experiments, the inoculated cards were stored under refrigeration for approximately
seven days prior to incubation. In other experiments, Vitek cards were incubated either
at 35°C for 16-20 hours or at room temperature for 48 hours.
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Determination of MlCs using the special cards. Following incubation of the cards, the
individual wells were examined visually for a change in color of the growth indicator.
If growth occurred in the presence of an antibiotic, the indicator changed from blue to
bright pink, indicating resistance to the antibiotic at that test concentration. Conversely,
lack of growth and color change of a well (i.e., remaining blue) indicated susceptibility
to that antibiotic concentration. The data were recorded by marking each pink well on a
specially designed data sheet which pictorially represented the configuration of that
card.
Determination of reference susceptibility results. For the stock culture isolates of
clinical origin, MICs of the study antibiotics were determined according to the broth
microdilution procedure advocated by the National Committee for Clinical Laboratory
Standards (NCCLS) (7). Specifically, cation adjusted Mueller-Hinton broth was used for
the non-fastidious species, and 3% lysed horse blood-supplemented cation adjusted
Mueller-Hinton broth was used for the Group A Streptococcus isolate (7).
Evaluation of susceptibility results. The MIC results determined using manual
readings of the special Vitek cards were compared either to the NCCLS expected ranges
for the ATCC control strains included in this study (7), or to NCCLS reference broth
microdilution susceptibility results determined on the test isolates.
RESULTS
Use of the specially configured Vitek cards and incorporation of alamarBlue TM as
a growth indicator allowed MICs to be visually determined without difficulty.
Relatively enriched, supplemented test media were used in order to provide rapid
growth of the organisms and sharply defined growth end-points with the indicator
system. Because of the clarity of the visual indicator system, each Vitek card could be
read and the results recorded on the special report sheets in less than 30 seconds per
card.
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Preliminary studies indicated that the Vitek test cards could be inoculated and
stored at 4°C for seven or eight days prior to incubation for 16-18 h at 35°C without
adversely affecting the test results (data not depicted). This approach was taken in
order to allow cards to be inoculated in a laboratory on the ground prior to launch of
the Space Shuttle, stored at refrigerated temperature, then incubated and read at a
convenient time during the mission using a special refrigerator-incubator module. This
would avoid the difficulties and safety concerns that would ensue from attempting to
standardize inoculum suspensions and inoculate the test cards during the flight.
There was reasonably good agreement between MICs determined in the special
Vitek cards and those determined by use of NCCLS reference methods using 35oc
incubation preceded by storage of the inoculated test cards at 4°C for seven to eight
days (see Tables 1-2). However, there were some antimicrobial agent-organism
combinations that resulted in MICs outside the NCCLS control range, or that were
different than the NCCLS reference procedure MIC values. The trimethoprim/
sulfamethoxazole MICs were generally higher in the experimental cards than when
determined by the standard NCCLS methodology, and the gentamicin, tetracycline, and
ciprofloxacin MICs likewise tended to be higher when determined using the Vitek
cards.
Room temperature incubation of the Vitek cards also provided reproducible
susceptibility test results that were generally comparable to the conventional 35oc
incubation temperature values (Tables 3 and 4). However, there were a number of off-
scale values that prevented a precise comparison of the MICs of some of the agents
included in this part of the study. In some instances the Vitek card MICs were lower
than the reference values (e.g., vancomycin and erythromycin with S. aureus ATCC
29213 and cefuroxime with E. coli ATCC 25922). More often, the Vitek card MICs were
higher than the reference values under room temperature incubation, as compared with
the same agents incubated at 35°C (Tables 1-4).
DISCUSSION
The risk of infectious diseasesis increasedduring spaceflight becauseof the crew
working and living in crowded conditions, the useof reclaimed/recycled air and water,
the absenceof infection isolation facilities, aswell ashuman physiological changes in
such an environment (1,8,9). In addition, the observed attenuation of the human
immune responsereported by American, Russian,and other international investigators
may be the most obvious reasonfor an increasedrisk of infectious diseasesduring
spaceflight (2,5,12).The dosageof antibiotics for infections that develop in spacemay
be affected by alterations in the absorption ratesand the pharmacokinetics and
pharmacodynamics of antibiotics that have been demonstrated during spaceflight (11).
Any decreasein microbial susceptibility to antibiotics during spaceflight could
markedly influence decisions on the management of infectious diseasesthat might
develop during long-duration missions. Severalprevious studies, although limited in
scope,suggestthat bacteria cultivated in microgravity may show increased resistanceto
certain antibiotics (3,4,6,10,13,14).
The methodology described in this report would allow simple determinations of
the antimicrobial susceptibility of severalbacterial speciesto be made by astronauts
during a SpaceShuttle mission. The color end point method of defining MICs can
provide on-board measurementsof susceptibility during the prolonged period of
microgravity that occursduring a shuttle flight. The feasibility of incubating the test
cards at ambient room temperature was demonstrated in this study in the event that
35°Cincubation could not beprovided on board the SpaceShuttle.
The MICs recorded in this ground-based pilot study were reproducible and
sometimes encompassedwithin the NCCLS referencerangeswith four ATCC control
strains commonly used in clinical laboratory susceptibility determinations. However,
someMIC values were higher when determined in the Vitek cards. Elevated
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trimethoprim/sulfamethoxazole MICs likely were the result of excessthymidine
contributed by the yeastextract added to the Mueller-Hinton broth to promote rapid,
luxuriant growth of the testorganisms. The tendency for higher gentamicin,
erythromycin, tetracycline, and ciprofloxacin MICs in the specialVitek cards, may have
been the result of a decreasein pH of the test media during prolonged storage of the
inoculated cards at 4°Cprior to the period of incubation. Future experiments will
include periodic pH measurements to assuremaintenance of the proper medium pH
during the pre-incubation period. Despite somedeviations from the standard reference
values, the MICs determined in the specialVitek cardswere quite reproducible, and
should allow recognition of any significant increaseor decreasein susceptibility that
might occur during the microgravity incubation period ascompared to the
simultaneously inoculated and incubated ground-based control card MICs. In order to
increase the statistical confidence of the MIC results determined in the test system by
the astronauts and the ground-based laboratory staff, eachorganism will be tested in
triplicate in ablinded fashion.
The goal of this proposed SpaceShuttle experiment using the susceptibility
procedures described herein is to confirm or refute thoseearlier reports of increased
resistanceby examining strains representing awider spectrum of clinically significant
speciesand to examine antibiotics of every clinically relevant classand mechanism of
action. The susceptibility testing methodology described in this report (specialVitek
cards and color growth indicator system)hasbeendeveloped to facilitate simple, fast,
and safehandling and reading by the SpaceShuttle crew with minimal crew time
required for the experiment. The authors arehopeful that the final version of this
experiment will be scheduled for a SpaceShuttle mission in the near future. The results
of that experiment should clarify whether there is any adverseeffect of microgravity on
the activities of antimicrobial agentsof various classesagainstcommonly encountered
bacterial pathogens.
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Table 1. MICs determined using specialVitek cardson NCCLS-ATCC control strains
following storage for 7-8days at 4°C, then incubation for 16-18h at 35 ° C.
S. aureus ATCC 29213
MIC (_g/ml)
(n) mode
range NCCLS
range
penicillin 7 1 1 0.25-1
oxacillin 7 0.25 0.25-0.5 0.12-0.5
cephalothin 7 0.12 0.06-0.25 0.12-0.5
vancomycin 7 1 1-2 0.5-2
erythromycin 7 0.5 0.5 0.12-0.5
trim/sulfa 7 4 1-4 _<0.5
ciprofloxacin 7 1 1 0.12-0.5
E. faecalis ATCC 29212
MIC (_tg/ml)
% within
NCCLS Range
100
100
57
100
100
0
0
(n) mode
range NCCLS
range
% within
NCCLS Range
penicillin 7 4 4 1-4 100
oxacillin 7 >2 >2 8-32 N.D.
cephalothin 7 >0.5 >0.5 8-32 N.D.
vancomycin 7 2 2 1-4 100
erythromycin 7 4 2-4 1-4 100
trim/sulfa 7 16 16->16 _<0.5 0
ciprofloxacin 7 4 2-4 0.25-2 29
MIC (pg/ml)
E. coli ATCC 25922
(n) mode
range NCCLS
range
ampicillin 6 8 4-8
amox/clav 6 8 8
cephalothin 6 16 8-32
cefuroxime 6 4 4
ceftazidime 6 0.25 0.12-0.25
gentamicin 6 - 1-2
tetracycline 6 4 4
trim/sulfa 6 0.25 0.25
ciprofloxacin 6 0.03 0.03
N.D. = Could not be determined based on concentrations tested.
2-8
2-8
4-16
2-8
0.06-0.5
0.25-1
1-4
<0.5
0.004-0.015
% within
NCCLS Range
100
100
83
100
100
50
100
100
0
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E. coli ATCC 35218 MIC (_g/ml)
(n) mode
range broth
microdilution
% within
_+ 1 dil
ampicillin 7 >32 >32 > 64 N.D.
amox/clav 7 16 8-16 4_16 a 100 b
cephalothin 7 16 16-32 16 100
cefuroxime 7 2 2 4 100
ceftazidime 7 0.12 0.12-0.25 0.25 100
gentamicin 7 1 1-2 0.5 43
tetracycline 7 8 4-8 2 43
trim/sulfa 7 1 0.5-1 0.5 100
ciprofloxacin 7 0.03 0.03 _< 0.25 N.D.
P. aeruginosa ATCC 27853
(n) mode
MIC (lug/ml)
range
ampicillin 7 >32 >32
amox/clav 7 >64 >64
cephalothin 7 >128 >128
cefuroxime 7 >8 >8
ceftazidime 7 2 2
gentamicin 7 4 4
tetracycline 7 >32 >32
trim/sulfa 7 >2 >2
ciprofloxacin 7 >0.12 >0.12
N.D. = Could not be determined based on concentrations tested.
NCCLS approved range
6 % within NCCLS approved range
NCCLS
range
1-4
0.5-2
8-32
8-32
0.25-1
% within
NCCLS range
N.D.
N.D.
N.D.
N.D.
100
0
0
N.D.
N.D.
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Table 2. MICs determined using specialVitek cards on strains of clinical origin
following storage for 7-8days at 4°C, then incubated for 16-18h at 35° C.
Group A Streptococcus 2726 MIC (_g/ml)
(n) mode range broth
microdilution
% within
+ 1 dil
penicillin 7 0.016 0.016 <0.015 100
oxacillin 7 0.06 <0.03-0.06 <0.125 100
cephalothin 7 0.03 0.03 <0.25 100
vancomycin 7 0.5 0.5 ___0.25 100
erythromycin 7 <0.06 <0.06 ___0.06 100
trim / sulfa 7 <0.25 <0.25-2 >2 43
ciprofloxacin 7 1 1 ___0.25 0
K. pneumoniae 2588 MIC (_g/ml)
(n) mode range broth
microdilution
% within
+ 1 dil
ampicillin 6 >32 >32 32 100
amox/clav 6 64 64 N.T. N.D.
cephalothin 6 >128 >128 >64 100
cefuroxime 6 2,4 2-4 8 50
ceftazidime 6 0.5 0.5 1 100
gentamicin 6 1 1-4 0.5 83
tetracycline 6 4,8 4-8 ___1 0
trim/sulfa 6 0.25 0.25 <0.25 100
ciprofloxacin 6 0.03 0.03 <0.25 N.D.
E. cloacae 2596
(n) mode
MIC (lag/ml)
range broth
microdilution
% within
+ 1 dil
ampicillin 6 >32 >32 16 0
amox/clav 6 64 64->64 N.T. N.D.
cephalothin 6 >128 >128 >64 N.D.
cefuroxime 6 4 4-8 32 0
ceftazidime 6 0.25 0.25 N.T. N.D.
gentamicin 6 1 1-4 0.5 83
tetracycline 6 8 8 4 100
16
trim/sulfa 6 0.25 0.25
ciprofloxacin 6 0.03 0.03-0.06
N°T.
<0.25
N.D. = Could not be determined based on concentrations tested.
N.T. = Not tested.
17
Table 3. MICs determined using specialVitek cardson NCCLS ATCC control strains
following storage for 7-8days at 4°C, then incubated for 48h at room temperature.
S. aureus ATCC 29213 MIC (/ag/ml)
(n) mode
range NCCLS
range
penicillin 6 0.5 0.25-1 0.25-1
oxacillin 6 0.25,0.5 0.25-0.5 0.12-0.5
cephalothin 6 0.06 0.015-0.06 0.12-0.5
vancomycin 6 0.25 0.25-0.5 0.5-2
erythromycin 6 0.06,0.25 0.06-0.25 0.12-0.5
trim/sulfa 6 0.25,1 0.25-1 _<0.5
ciprofloxacin 6 1 0.25-1 0.12-0.5
% within
NCCLS Range
100
100
0
5O
5O
50
50
E. faecalis ATCC 29212
(n) mode
MIC (_tg/ml)
range NCCLS
range
% within
NCCLS Range
penicillin 12 4 4 1-4 100
oxacillin 12 >2 >2 8-32 N.D.
cephalothin 12 >0.5 >0.5 8-32 N.D.
vancomycin 12 2 2 1-4 100
erythromycin 12 >16 16->16 1-4 0
trim/sulfa 12 16 8->16 <0.5 0
ciprofloxacin 12 4 4 0.25-2 0
MIC (_tg/ml)
range NCCLS
range
E. coli ATCC 25922
(n) mode
ampicillin 9 4 4-8
amox/clav 9 8 4-8
cephalothin 9 <4 <4-8
cefuroxime 9 2 1-2
ceftazidime 9 0.12 0.12-0.25
gentamicin 9 4 4
tetracycline 9 4 4-8
trim/sulfa 9 0.5 0.25-0.5
ciprofloxacin 9 0.008 0.008
2-8
2-8
4-16
2-8
0.06-0.5
0.25-1
1-4
<0.5
0.004-0.015
N.D. = Could not be determined based on concentrations tested.
% within
NCCLS Range
100
100
100
67
100
0
78
100
100
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E. coli ATCC 35218 MIC (lug/ml)
(n) mode
range
ampicillin 9 >32 >32
amox/clav 9 8 8-16
cephalothin 9 8 <4-32
cefuroxime 9 1 <0.5-2
ceftazidime 9 0.12 <0.06-0.12
gentamicin 9 2,4 1-4
tetracycline 9 8 <1-8
trim/sulfa 9 1 <0.06-1
ciprofloxacin 9 0.016 <0.004-0.016
broth
microdilution
> 64
4-16 a
16
4
0.25
0.5
2
0.5
< 0.25
% within
+ 1 dil
N.D.
100 b
89
33
78
22
11
78
N.D.
P. aeruginosa ATCC 27853
(n) mode
MIC (lag/ml)
range NCCLS
range
% within
NCCLS Range
ampicillin 9 >32 >32 N.D.
amox/clav 9 >64 >64 N.D.
cephalothin 9 >128 >128 - N.D.
cefuroxime 9 >8 >8 - N.D.
ceftazidime 9 2 2 1-4 100
gentamicin 9 4 4 0.5-2 0
tetracycline 9 >32 >32 8-32 0
trim/sulfa 9 >2 >2 8-32 N.D.
ciprofloxacin 9 >0.12 >0.12 0.25-1 N.D.
N.D. = Could not be determined based on concentrations tested.
a NCCLS approved range
b% within NCCLS approved range
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Table 4. MICs determined using specialVitek cards on strains of clinical origin
following storage for 7-8days at 4° C, then incubated for 48h at room temperature.
Group A Streptococcus 2726 MIC (gg/ml)
(n) mode range broth
microdilution
penicillin 12 0.008
oxacillin 12 <0.03
cephalothin 12 0.015
vancomycin 12 0.25
erythromycin 12 <0.06
trim/sulfa 12 <0.25
ciprofloxacin 12 1
% within
+ 1 dil
___0.008-0.016 ___0.015 100
___0.03-0.06 <0.12 N.D
<0.008-0.015 _<0.25 N.D.
<0.12-0.25 _<0.25 100
<0.06 _<0.06 100
-<0.25-0.5 >2 0
0.5-1 -<0.25 58
K. pneumoniae 2588
(n) mode
MIC (gg/ml)
range broth % within
microdilution + 1 dil
ampicillin 12 >32 >32 32 100
amox/clav 12 >64 >64 N.T. N.D.
cephalothin 12 >128 >128 >64 100
cefuroxime 12 4 4-8 8 100
ceftazidime 12 0.5 0.5-2 1 100
gentamicin 12 2 2-4 0.5,1 67
tetracycline 12 8 4->32 ___1 0
trim / sulfa 12 0.5 0.25-0.5 _<0.25 100
ciprofloxacin 12 0.03 0.03-0.06 ___0.25 N.D.
E. cloacae 2596
(n) mode
MIC (gg/ml)
range broth % within
microdilution + 1 dil
ampicillin 12 >32 >32 16 0
amox/clav 12 >64 >64 N.T. N.D.
cephalothin 12 >128 >128 >64 100
cefuroxime 12 8 8->8 32 0
ceftazidime 12 0.05 0.05 N.T. N.D.
gentamicin 12 2 2-4 0.5 0
tetracycline 12 8 8->32 4 50
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trim/sulfa 12 0.5 0.12-0.5
ciprofloxacin 12 0.03 0.016-0.06
N.D. = Could not be determined basedon concentrations tested.
N.T. = Not tested
N°T°
<0.25
21
